Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

MRM Health NV

Request full access

Microbiome-based therapeutics using a proprietary platform to design, optimise, and manufacture live bacterial consortia as drugs

Ghent, BelgiumFounded 2020Biotech & Life Sciences

About MRM Health NV

MRM Health NV is a clinical-stage biopharmaceutical company, established in 2020 and headquartered in Ghent, Belgium. The company was founded by CEO Dr. Sam Possemiers, who brings over 15 years of expertise in gut microbiology and host-microbiome interactions from both academic and industrial settings. His entrepreneurial background includes co-founding ProDigest and MRM Technologies, the latter of which, a center for microbiome R&D, established MRM Health as a joint venture with the life sciences research institute VIB.

The company focuses on developing live biotherapeutic products by targeting the human microbiome to address a range of inflammatory, central nervous system, and metabolic diseases. MRM Health's business model revolves around the discovery, development, and potential commercialization of these novel therapeutics. This is achieved through a combination of in-house programs and strategic collaborations, such as its partnership with IFF (formerly DuPont Nutrition & Biosciences) to co-develop treatments for metabolic diseases like Type 2 Diabetes. The company is backed by a consortium of local and international investors, including Ackermans & van Haaren, IFF, Qbic II, and VIB.

At the core of its operations is the proprietary CORAL® platform, a technology designed to overcome key challenges in microbiome therapeutic development. This platform integrates a bioinformatics-guided discovery engine with a unique optimization and manufacturing process. It allows for the rational selection of 5 to 10 bacterial strains that work synergistically and can be produced as a single drug substance, streamlining development and enhancing scalability. A key feature is the use of tools like the Simulator of the Human Intestinal Microbial Ecosystem (SHIME®) to test consortia before clinical trials.

MRM Health's lead product candidate, MH002, is an optimized consortium of six commensal strains aimed at treating Inflammatory Bowel Diseases. The company has reported positive topline results from a Phase 2a clinical study in mild-to-moderate Ulcerative Colitis and is also evaluating MH002 in patients with Pouchitis, an orphan disease. Beyond its lead program, the pipeline includes preclinical candidates for Parkinson's Disease and autoimmune disorders.

Source: Dealroom company data

At a glance

Status
Operational
Employees
41
Open positions
None listed
Dealroom signal
73.3/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Spinout, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

4 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES BOther financing Sep 2025 $61M $242M Flanders Institute for Biotechnology · BIOCODEX · Athos · Qbic Fund ↗
GRANTOther financing Mar 2023 $2.2M — Undisclosed ↗
Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

MRM Health NV website traffic

Latest recorded traffic for MRM Health NV is 10 monthly website visits, down 99.3% over the last three months. MRM Health NV's team grew 0% over the past year.

Latest monthly visits10 3-month web change-99.3% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

MRM Health NV in the Ghent ecosystem

Live from Dealroom

The MRM Health NV office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

11 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A9 investors entered at this stage

  • Qbic Fund
  • Ackermans & van Haaren
  • DuPont
  • Flanders Institute for Biotechnology
  • BIOCODEX
  • Athos
  • SFPIM
  • BNP Paribas Fortis
  • OMX Ventures

Other known investors2 additional known investors

  • Ghent University
  • KU Leuven
Team profiled 6 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
5 countries with
team presence
🇧🇪 Belgium77.8%
🇫🇷 France7.4%
🇺🇸 United States7.4%
🇳🇱 Netherlands3.7%
🇮🇪 Ireland3.7%
5 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about MRM Health NV on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See MRM Health NV’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.